Volume 38, Issue 9 pp. 817-820

Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia

B. Evatt

B. Evatt

Bruce Evatt, MD, Chief, Hematologic Diseases Branch, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, 1600 Clifton Road, NE, MS E64, Atlanta, GA 30333.

Search for more papers by this author
H. Austin

H. Austin

Harland Austin, DSc, Professor, the Rolins School of Public Health, Emory University, Atlanta GA.

Search for more papers by this author
E. Barnhart

E. Barnhart

Elizabeth Barnhart, MPH, Project Coordinator, the Rolins School of Public Health, Emory University, Atlanta GA.

Search for more papers by this author
L. Schonberger

L. Schonberger

Lawrence Schonberger, MD, Assistant Director for Public Health, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention.

Search for more papers by this author
L. Sharer

L. Sharer

Leroy Sharer, MD, Professor, Department of Pathology, UMD, The New Jersey Medical School, Newark, NJ.

Search for more papers by this author
R. Jones

R. Jones

Robert Jones, MD, Colonel, Medical Corps, US Army Reserve, Washington, DC.

Search for more papers by this author
S. DeArmond

S. DeArmond

Stephen DeArmond, MD, Professor, Department of Pathology, University of California School of Medicine, San Francisco, California.

Search for more papers by this author
First published: 27 February 2003
Citations: 65

Abstract

BACKGROUND: Although Creutzfeldt-Jakob disease (CJD) has been shown to be transmissible through blood components in rodent models, no human blood-to-blood transmission has been documented. If blood transmission were possible in humans, persons with hemophilia in the United States would be at higher risk of contracting CJD, because they receive large numbers of blood components. Nearly one-half of the hemophilia population contracted HIV in the 1980s, and many of these people have since died with neurologic complications. This study investigated whether some hemophilia patients with neurologic disorders may have died with CJD.

STUDY DESIGN AND METHODS: Hemophilia treatment Centers across the United States were invited to participate in this retrospective surveillance study. The centers were asked to send any available formalin-fixed paraffin block brain samples from hemophilia decedents. Slides were prepared at the Centers for Disease Control and Prevention and reviewed by three expert neuropathologists. Two slides were stained for the prion protein at the request of one of the neuropathologists.

RESULTS: Specimens from 24 decedents with genetic bleeding disorders were collected and reviewed. The panel found no evidence of CJD in any of the specimens.

CONCLUSIONS: Although the study sample is small, these results support the growing evidence that CJD is not being transmitted in the nation's blood supply.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.